In this update KOLs reflect on the promising Phase Ib data for Roche’s monoclonal antibody (mAb), atezolizumab, in combination with nab-paclitaxel for patients with metastatic triple- negative breast cancer (mTNBC); the US Food and Drug Administration (FDA) awarding Breakthrough Therapy Designation to Immunomedics’ lead antibody drug conjugate (ADC), sacituzumab govitecan (IMMU-132), along with reaction to the Phase II trials of IMMU-132 in late stage TNBC; and KOL reaction to an expanded indication to Pfizer’s Ibrance (palbociclib) based on findings from the Phase III PALOMA-3 trial.
Key Questions Answered in this Update Bulletin:
How do KOLs feel about the potential of immunotherapy in the area of TNBC, including comparisons with PARP inhibitors? What are KOLs first impressions to the Phase Ib data of Roche’s atezolizumab in combination with nab-paclitaxel in patients with mTNBC, what are their concerns? How does the approach of immunotherapy compare to that of PARP inhibitors? Where in the treatment paradigm could an agent such as atezolizumab be used? What are KOLs first impressions to the Phase II data for Immunomedics’ lead antibody drug conjugate sacituzumab govitecan in patients with late stage TNBC? Where in the treatment paradigm could an agent such as sacituzumab govitecan be used? How do KOLs react to the supplemental filing and subsequent granting of an expanded indication to Pfizer’s Ibrance (palbociclib) based on findings from the Phase III PALOMA-3 trial? What impact will the granting of this expanded indication have on prescriptions of Ibrance and on those of Afinitor?
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.